The Therapeutic Effect of Hemodialysis Biofilm Technology on Patients with Acute Renal Failure After Acute Streptococcal Infection

Abstract

We aimed to study the therapeutic effect of hemodialysis biofilm (HDB) technology on acute renal failure (ARF) after acute streptococcal infection (ASI). 50 patients having renal failure after ASI admitted to Xuchang hospital were selected and rolled into two groups according to the self-selected therapeutic methods. Patients in observation group (group A) received HDB technology treatment, while patients in the control group (group B) received non-hemodialysis (NHD) treatment. The biochemical indicators of patients in two groups before and after receiving the treatment were observed and compared, which include parathyroid (PTH), β2-microglobulin (β2-MG), blood urea nitrogen (BUN), creatinine (Cre), and K+ ion content. In addition, the hospital stay, the complication incidence, and the total efficacy of the two groups were compared and analyzed. After treatment, the biochemical indicators of the two groups of patients were reduced; the levels of PTH, β2-MG, BUN, and Cre of patients in group A were much lower than those of patients in group B, and group A has greater decline. In group A, 16 cases were cured and 8 cases were improved, with a TER of 92.3%; 11 cases were cured and 10 cases were improved in group B, with a TER of 83.6%, so there was statistically obvious difference between the two groups (P < 0.05). The average hospital stays in the group A and group B was respectively 13.8 days and 24.9 days, showing statistical difference (P < 0.05). The complication incidences in groups A and B were 16.6% and 45.4%, respectively, with statistically significant difference (P < 0.05). HDB technology was beneficial to the repair of damaged renal function cells, could promote the recovery of renal function in patients, and could effectively reduce mortality. Therefore, it was worthy of clinical promotion.